Development and validation of an inflammatory-based nomogram for predicting arteriovenous fistula maturation failure in end-stage renal disease patients

开发和验证基于炎症指标的列线图,用于预测终末期肾病患者动静脉瘘成熟失败

阅读:2

Abstract

BACKGROUND AND HYPOTHESIS: Arteriovenous fistula (AVF) is regarded as the most effective vascular access for hemodialysis in patients with end-stage renal disease (ESRD).However, research investigating the relationships between the systemic inflammation response index (SIRI), the triglyceride-glucose index combined with body mass index (TyG-BMI), and the high-sensitivity C-reactive protein to albumin ratio (HRR) with AVF maturation is still limited. METHODS: We included all ESRD patients undergoing first-time AVF creation between March and August 2024 at Haidian Hospital, Beijing (n = 249). To evaluate predictors of AVF maturation failure, we analyzed preoperative clinical/laboratory data and follow-up ultrasound assessments using restricted cubic spline models for dose-response relationships (SIRI, TyG-BMI, HRR). Multivariable Cox models identified independent risk factors, and a predictive nomogram was developed and validated through C-index and calibration plots. RESULTS: This study included 249 patients (73.5% AVF maturation rate). Restricted cubic spline analysis revealed linear associations between AVF maturation and SIRI (p-overall = 0.047), TyG-BMI (p-overall = 0.039), and HRR (p-overall = 0.026). Multivariable Cox regression identified three independent predictors: SIRI (HR = 1.69, 95%CI:1.45-1.96), TyG-BMI (HR = 2.68, 95%CI:1.62-4.41), and HRR (HR = 1.44, 95%CI:1.28-1.61) (all p < 0.001). The biomarker-based nomogram showed strong predictive accuracy, with calibration curves demonstrating excellent observed-versus-expected agreement. CONCLUSION: Non-maturation of AVF was independently associated with three inflammation-based biomarkers, namely SIRI, TyG-BMI, and HRR. High predictive accuracy was demonstrated by the nomogram incorporating these markers, supporting its use for the early identification of high-risk patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。